药品信息:
--------------------------------------------------------------- 详细处方信息以本药内容附件PDF文件(201941619334628.pdf)的“原文Priscribing Information”为准 --------------------------------------------------------------- 部分中文Ozempic处方资料(仅供参考)
【英文名称】Ozempic
【适应症】
OZEMPIC是一种胰高血糖素样肽1(GLP-1)受体激动剂,表示作为饮食和运动的辅助手段,可改善2型糖尿病患者的血糖控制(1)。
使用限制:
---不推荐作为对饮食和运动控制不充分的患者的一线治疗(1,5.1)。
---尚未研究过有胰腺炎病史的患者。 考虑另一种抗糖尿病治疗(1,5.2)。
---不适用于1型糖尿病或糖尿病酮症酸中毒治疗(1)。
【禁忌】
甲状腺髓样癌或2型多发性内分泌肿瘤综合征患者的个人或家族史(4)。
已知对OZEMPIC或任何产品成分过敏(4)。
【用法和用量】
每周一次,每次0.25毫克。 4周后,每周一次将剂量增加至0.5mg。 如果在至少4周后需要额外的血糖控制,每周一次增加至1毫克(2.1)。
每天一次,每周一次,无论是否进餐(2.1)。
如果错过剂量,则在错过剂量后的5天内给药(2.1)。
在腹部,大腿或上臂皮下注射(2.2)。
【INDICATIONS AND USAGE】
OZEMPIC is a glucagon-like peptide 1 (GLP-1) receptor agonist indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus (1).
Limitations of Use:
---Not recommended as first-line therapy for patients inadequately controlled on diet and exercise (1, 5.1).
---Has not been studied in patients with a history of pancreatitis. Consider another antidiabetic therapy (1, 5.2).
---Not indicated for use in type 1 diabetes mellitus or treatment of diabetic ketoacidosis (1).
【DOSAGE AND ADMINISTRATION】
Start at 0.25 mg once weekly. After 4 weeks, increase the dose to 0.5 mg once weekly. If after at least 4 weeks additional glycemic control is needed, increase to 1 mg once weekly (2.1).
Administer once weekly at any time of day, with or without meals (2.1).
If a dose is missed administer within 5 days of missed dose (2.1).
Inject subcutaneously in the abdomen, thigh, or upper arm (2.2).
【CONTRAINDICATIONS】
Personal or family history of medullary thyroid carcinoma or in patients with Multiple Endocrine Neoplasia syndrome type 2 (4).
Known hypersensitivity to OZEMPIC or any of the product components (4).
--------------------------------------------------------------- 详细处方信息以本药内容附件PDF文件(201941619334628.pdf)的“原文Priscribing Information”为准 --------------------------------------------------------------- |